Aziz Zaanan
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 149 publications
Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions.
Journal: ESMO gastrointestinal oncology
Published: June 12, 2026
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2026
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP).
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 04, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.
Journal: Investigational new drugs
Published: January 29, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 06, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Journal: Nature medicine
Published: November 07, 2025
Plasma Protein Biomarkers to Detect Early Gastric Preneoplasia and Cancer: A Prospective Study.
Journal: International journal of molecular sciences
Published: September 09, 2025
Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.
Journal: NPJ precision oncology
Published: August 06, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 09, 2025
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI).
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 04, 2025
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX - Authors' reply.
Journal: The Lancet. Oncology
Published: June 27, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 18, 2025
Last Updated: 09/26/2026